PEO-PPO block copolymers for passive micellar targeting and overcoming multidrug resistance in cancer therapy

Current Drug Targets

Volumn 12, Issue 8, 2011, Pages 1112-1130

  Alvarez Lorenzo, C ^a   Sosnik, A ^b,c   Concheiro, A ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^c National Science Research Council ^*  (Argentina)

Author keywords

Anticancer therapy; Drug solubilization; Epr effect; P glycoprotein inhibition; Poloxamer; Poloxamine; Polymeric micelle

Indexed keywords

AMPHOPHILE; BENZOPORPHYRIN DERIVATIVE; CAMPTOTHECIN; CISPLATIN; CREMOPHOR; EPIDERMAL GROWTH FACTOR; EPIRUBICIN; ETHYLENE OXIDE; METHOTREXATE; PACLITAXEL; POLOXAMER; PROPYLENE OXIDE; RAPAMYCIN; TETRONIC; TWEEN; TYRPHOSTIN; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CRITICAL MICELLE CONCENTRATION; DRUG HALF LIFE; DRUG SAFETY; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; HYPERPLASIA; MULTIDRUG RESISTANCE; NEOINTIMA; NEOPLASM; REVIEW; SOLID TUMOR;

ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; EXCIPIENTS; HUMANS; MICELLES; NEOPLASMS; POLYETHYLENE GLYCOLS; POLYMERS;

EID: 79959310261     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011795906615     Document Type: Review

References (204)

1. Le Garrec D, Gori S, Luo L, et al. Poly(N-vinylpyrrolidone)-blockpoly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation. J Control Release 2004; 99: 83-101.
2. Hatefi A, Knight D, Amsden B. A biodegradable injectable thermoplastic for localized campthotecin delivery. J Pharm Sci 2004; 93: 1195-204.
3. Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 2005; 4: 363-73.
4. Chadha R, Kapoor VK, Thakur D, Kaur R, Arora P, Jain DVS. Drug carrier systems for anticancer agents: a review. J Sci Ind Res 2008; 67: 185-97.
5. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. The Oncologist 2009; 13: 248-60.
6. Yokoyama M. Polymeric micelles as a new drug carrier system and their required considerations for clinical trials. Expert Opin Drug Deliv 2010; 7: 145-58.
7. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005; 109: 169-88.
8. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Del Rev 2011; 63: 131-5.
9. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 2001; 47: 113-31.
10. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release 2001; 73: 137-72.
11. Adams ML, Lavasanifar A, Kwon GS. Amphiphilic block copolymers for drug delivery. J Pharm Sci 2003; 92: 1343-55.
12. Bae YH, Yin H. Stability issues of polymeric micelles. J Control Release 2008; 131: 2-4.
13. Barratt G. Colloidal drug carriers: achievements and perspectives. Cell Mol Life Sci 2003; 60: 21-37.
14. Moghimi SM, Muir IS, Illum L, Davis SS, Kolb-Bachofen V. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim Biophys Acta 1993; 1179: 157-65.
15. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic® block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 2002; 82: 189-212.
16. DesNoyer JR, McHugh AJ. The effect of Pluronic on the protein release kinetics of an injectable drug delivery system. J Control Release 2003; 86: 15-24.
17. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005; 109: 169-88.
18. Aliabadi HM, Brocks DR, Lavasanifar A. Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution. Biomaterials 2005; 26: 7251-9.
19. Croy SR, Kwon GS. Polymeric micelles for drug delivery. Curr Pharm Design 2006; 12: 4669-84.
20. Yokoyama M, Opanasopit P, Okano T. Polymer design and incorporation method for polymeric micelle carrier system containing water-insoluble anti-cancer agent camptothecin. J Drug Target 2004; 12: 373-84.
21. Li Y, Kwon GS. Methotrexate ester of poly(ethylene oxide)-blockpoly(2-hydroxyethyl-L-aspartamide). Part I: effects of the level of methotrexate conjugation on the stability of micelles and on drug release. Pharm Res 2000; 157: 607-11.
22. Aliabadi HM, Shahin M, Brocks DR, Lavasanifar A. Disposition of drugs in block copolymer micelle delivery systems - From discovery to recovery. Clin Pharmacokin. 2008; 47: 619-34.
23. Ulbrich K, Subr V. Polymeric anticancer drugs with pH-controlled activation. Adv Drug Del Rev 2004; 56, 1023-50.
24. Mondon K, Gurny R, Möller M. Colloidal drug delivery systems - Recent advances with polymeric micelles. Chimia 2008; 62: 832-840.
25. Mahmud A, Xiong XB, Aliabadi HM, Lavasanifar A. Polymeric micelles for drug targeting. J Drug Targeting 2007; 15: 553-84.
26. Blanco E, Kessinger CW, Sumer BD, Gao J. Multifunctional micellar nanomedicine for cancer therapy. Exp Biol Med 2009; 234: 123-31.
27. Sant VP, Smith D, Leroux JC. Novel pH-sensitive supramolecular assemblies for oral delivery of poorly water soluble drugs: preparation and characterization. J Control Release 2004; 97: 301-12.
28. Jones MC, Ranger M, Leroux JC. pH-sensitive unimolecular polymeric micelles: synthesis of a novel drug carrier. Bioconjugate Chem 2006; 14: 774-81.
29. Shim WS, Kim SW, Choi EK, Park HJ, Kim JS, Lee DS. Novel pH sensitive block copolymer micelles for solvent free drug loading. Macromol Biosci 2006; 6: 179-86.
30. Rapoport N. Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery. Prog Polymer Sci 2007; 32: 962-90.
31. Alvarez-Lorenzo C, Concheiro A. Intelligent drug delivery systems: polymeric micelles and hydrogels. Mini-Rev Med Chem 2008; 8: 1065-74.
32. Alvarez-Lorenzo C, Bromberg L, Concheiro A. Light-sensitive intelligent drug delivery systems. Photochem Photobiol 2009; 85: 848-60.
33. Kabanov AV, Alkhov VYu. Pluronic® block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers. Critical Rev Therap Drug Carrier Syst 2002; 19: 1-72.
34. Alexandridis P, Hatton TA. Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer surfactants in aqueous solutions and interfaces: thermodynamics, structure, dynamics and modelling. Colloids Surf A: Physicochem Eng Asp 1995; 96: 1-46.
35. Chiappetta DA, Sosnik A. Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: Improved hydrosolubility, stability and bioavailability of drugs. Eur J Pharm Biopharm 2007; 66: 303-17.
36. Wu J, Xu Y, Dabros T, Hamza H. Effect of EO and PO positions in nonionic surfactants on surfactant properties and demulsification performance. Colloids Surf A: Physicochem Eng Asp 2005; 252: 79-85.
37. Moghimi SM, Hunter AC. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. TIBTECH 2000; 18: 412-20.
38. McLain CV. Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int J Toxicol 2008; 27: 93-128.
39. Grindel JM, Jaworski T, Piraner O, Emanuele RM, Balasubramanian M. Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans. J Pharm Sci 2002; 91: 1936-47.
40. www2.basf.us/performancechemical/pdfs/Pluronic_NF_Grades.pdf (accessed April 2010).
41. Subbaraman LN, Bayer S, Gepr S, et al. Rewetting drops containing surface active agents improve the clinical performance of silicone hydrogel contact lenses. Optometry Vis Sci 2006; 83: 143-51.
42. Batrakova E, Lee S, Li S, Venne A, Alakhov V, Kabanov A. Fundamental relationships between the composition of Pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm Res 1999; 16: 1373-9.
43. Gonzalez-Lopez J, Alvarez-Lorenzo C, Taboada P, Sosnik A, Sandez-Macho I, Concheiro A. Self-associative behavior and drug solubilizing ability of poloxamine (Tetronic) block copolymer. Langmuir 2008; 24: 10688-97.
44. Oh KT, Bronich TK, Kabanov AV. Micellar formulations for drug delivery based on mixtures of hydrophobic and hydrophilic Pluronic® block copolymers. J Control Release 2004; 94: 411-22.
45. Attwood D, Zhou Z, Booth C. Poly(ethylene oxide) based copolymers: solubilisation capacity and gelation. Expert Opin Drug Deliv 2007; 4: 533-46.
46. Alexandridis P, Hatton TA. Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer surfactants in aqueous solutions and interfaces: thermodynamics, structure, dynamics and modelling. Colloids Surf A: Physicochem Eng Asp 1995; 96: 1-46.
47. Vadnere M, Amidon GL, Lindenbaum S, Haslam JL. Thermodynamic studies on gel-sol transition of some Pluronic polyols. Int J Pharm 1984; 22: 207-18.
48. Mortensen K, Pedersen JS. Structural study on the micelle formation of poly(ethylene oxide)-poly(propylene oxide)- poly(ethylene oxide) triblock-copolymer in aqueous solution. Macromolecules 1993; 26: 805-12.
49. Ruel-Gariepy E, Leroux JC. In situ-forming hydrogels-review of temperature-sensitive systems. Eur J Pharm Biopharm 2004; 58: 409-26.
50. Bromberg L. Polymeric micelles in oral chemotherapy. J Control Release 2008; 128: 99-112.
51. Dong J, Chowdhry BZ, Leharne SA. Surface activity of poloxamines at the interfaces between air-water and hexane-water. Colloids Surf A: Physicochem Eng Asp 2003; 212: 9-17.
52. Alvarez-Lorenzo C, Gonzalez-Lopez J, Fernandez-Tarrio M, Sandez-Macho I, Concheiro A. Tetronic micellization, gelation and drug solubilization: Influence of pH and ionic strength. Eur J Pharm Biopharm 2007; 66: 244-52.
53. Alvarez-Lorenzo C, Rey-Rico A, Sosnik A, Taboada P, Concheiro A. Poloxamine-based nanomaterials for drug delivery. Frontiers Biosci 2010; E2: 424-40.
54. Sosnik A, Sefton MV. Methylation of poloxamine for enhanced cell adhesion. Biomacromolecules 2006; 7: 331-8.
55. Sosnik A, Sefton MV. Semi-synthetic collagen/poloxamine matrices for tissue engineering applications. Biomaterials 2005; 26: 7425-35.
56. Hurter PN, Hatton TA. Solubilization of polycyclic aromatic hydrocarbons by poly(ethylene oxide-propylene oxide) block copolymer micelles: Effects of polymer structure. Langmuir 1992; 8: 1291-9.
57. Dong J, Chowdhry BZ, Leharne SA. Solubilisation of polyaromatic hydrocarbons in aqueous solutions of poloxamine T803. Colloids Surf A: Physicochem Eng Asp 2004; 246: 91-8.
58. Chiappetta DA, Degrossi J, Lizarazo RA, Salinas DL, Martínez F, Sosnik A. Molecular implications in the solubilization of the antibacterial agent triclocarban by means of branched poly(ethylene oxide)-poly(propylene oxide) polymeric micelles. In: Polymer Aging, Stabilizers and Amphiphilic Block Copolymers, Nova Publishers, Segewicz L, Petrowsky M (Eds.), Hauppauge, N.Y. 2010, Chapter 5.
59. Chiappetta DA, Degrossi J, Teves S, D'Aquino M, Bregni C, Sosnik A. Triclosan-loaded poloxamine micelles for enhanced antibacterial activity against biofilm. Eur J Pharm Biopharm 2008; 69: 535-45.
60. Spancake CW, Mitra AK, Kildsig DO. Kinetics of aspirin hydrolysis in aqueous solutions and gels of poloxamines (Tetronic 1508) - Influence of microenvironment. Int J Pharm 1991; 75: 231-9.
61. Miyazaki S, Oda M, Takada M, Attwood D. Thermally gelling poloxamine synperonic T908 solution as a vehicle for rectal drug delivery. Biol Pharm Bull 1995; 18: 1151-3.
62. Chiappetta DA, Hocht C, Taira C, Sosnik A. Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailaibility. Nanomedicine 2010; 5: 11-23.
63. Chiappetta DA, Hocht C, Sosnik A. A highly concentrated and taste-improved aqueous formulation of efavirenz for a more appropriate paediatric management of the anti-HIV therapy. Curr HIV Res 2010; 8: 23-31.
64. Chiappetta DA, Alvarez-Lorenzo C, Rey-Rico A, Taboada P, Concheiro A, Sosnik A. N-alkylation of poloxamines modulates micellar encapsulation and release of the antiretroviral efavirenz. Eur J Pharm Biopham 2010; 76: 24-37.
65. Gust R, Bernhardt G, Spruss T, et al. Development of a parenterally administrable hydrosol preparation of the third generation platinum complex [(±)-1,2-bis(4-fluorophenyl)ethylenediamine] dichloroplatinum(II). Part 1. Preparation and studies on the stability and antitumor activity. Archiv Pharmazie 1995; 328: 645-53.
66. Batrakova EV, Dorodnych TY, Klinskii EY, et al. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anticancer activity. Br J Cancer 1996; 74: 1545-52.
67. Gao ZG, Fainb HD, Rapoport N. Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers. Mol Pharm 2004; 1: 317-30.
68. Munshi N, Rapoport N, Pitt WG. Ultrasonic activated drug delivery from Pluronic P-105 micelles. Cancer Lett. 1997; 118: 13-9.
69. Rapoport N, Herron JN, Pitt WG, Pitina L. Micellar delivery of doxorubicin and its paramagnetic analog, ruboxyl, to HL-60 cells: effect of micelle structure and ultrasound on the intracellular drug uptake. J Control Release 1999; 58: 153-62.
70. Husseini GA, El-Fayoumi RI, O'Neill KL, Rapoport NY, Pitt WG. DNA damage induced by micellar-delivered doxorubicin and ultrasound: comet assay study. Cancer Lett 2000; 154: 211-6.
71. Husseini GA, Rapoport NY, Christensen DA, Pruitt JD, Pitt WG. Kinetics of ultrasonic release of doxorubicin from pluronic P105 micelles. Colloids Surf B: Biointerf 2002; 24: 253-64.
72. Rapoport N. Combined cancer therapy by micellar-encapsulated drug and ultrasound. Int J Pharm 2004; 277: 155-62.
73. Stevenson-Abouelnasr D, Husseini GA, Pitt WG. Further investigation of the mechanism of doxorubicin release from P105 micelles using kinetic models. Colloids Surf B: Biointerf 2007; 55: 59-66.
74. McNealy TL, Trojan L, Knoll T, Alken P, Michel MS. Micelle delivery of doxorubicin increases cytotoxicity to prostate carcinoma cells. Urol Res 2004; 32: 255-60.
75. Batrakova EV, Kelly DL, Li S, et al. Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: Pluronic P85. Mol Pharm 2006; 3: 113-23.
76. Hioka N, Chowdhary RK, Chansarkar N, Delmarre D, Sternberg E, Dolphin D. Studies of a benzoporphyrin derivative with Pluronics. Can J Chem 2002; 80: 1321-6.
77. Chowdhary RK, Chansarkar N, Sharif I, Hioka N, Dolphin D. Formulation of benzoporphyrin derivatives in Pluronics. Photochem Photobiol 2003; 77: 299-303.
78. Barreiro Iglesias R, Bromberg L, Temchenko M, Hatton TA, Concheiro A, Alvarez-Lorenzo C. Solubilization and stabilization of camptothecin in micellar solutions of pluronic-g-poly(acrylic acid) copolymers. J Control Release 2004; 97: 537-49.
79. Sezgin Z, Yüksel N, Baykara T. Preparation and characterization of polymeric micelles for solubilization of poorly soluble anticancer drugs. Eur J Pharm Biopharm 2006; 64: 261-8.
80. Alakhov V, Pietrzynski G, Patel K, Kabanov A, Bromberg L, Hatton TA. Pluronic block copolymers and Pluronic poly(acrylic acid) microgels in oral delivery of megestrol acetate. J Pharm Pharmacol 2004; 56: 1233-41.
81. Han LM, Guo J, Zhang LJ, Wang QS, Fang XL. Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. Acta Pharmacol Sin 2006; 27: 747-53.
82. Sezgin Z, Yuksel N, Baykara T. Investigation of pluronic and PEGPE micelles as carriers of meso-tetraphenyl porphine for oral administration. Int J Pharm 2007; 332: 161-7.
83. Edelman ER, Simons M, Sirois MG, Rosenberg RD. C-myc in vasculoproliferative disease. Circ Res 1995; 76: 176-82.
84. Castier Y, Chemla E, Nierat J, et al. The activity of c-myb antisense oligonucleotide to prevent intimal hyperplasia is non-specific. J Carciovasc Surg 1998; 39: 1-7.
85. DiBiase MD, Rhodes CT. Formulation and evaluation of epidermal growth factor in Pluronic F-127 gel. Drug Dev Ind Pharm 1996; 22: 823-31.
86. Gottsauner-Wolf M, Jang Y, Lincoff AM, et al. Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin- 47 on smooth-muscle cell proliferation in a rat carotid ballooninjury model. Am Heart J 1997; 133: 329-34.
87. Schachner T, Zou Y, Oberhuber A, et al. Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. Ann Thoracic Surg 2004; 77: 1580-5.
88. Schachner T, Oberhuber A, Zou Y, et al. Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts. Eur J Cardio-Thoracic Surg 2005; 27: 302-6.
89. Pluta J, Karolewicz B. In vitro studies of the properties of thermosensitive systems prepared on Pluronic F-127 as vehicles for methotrexate for delivery to solid tumours. Polim Med 2006; 36: 37-53.
90. Alvarez-Lorenzo C, Concheiro A. Polymeric micelles as drug stabilizers: the camptothecin and simvastatin cases. J Drug Deliv Sci Tech 2010; 20: 249-57.
91. O'Leary J, Muggia FM. Camptothecins: a review of their development and schedules of administration. Eur J Cancer 1998; 34: 1500-8.
92. Giovanella BC, Harris N, Mendoza J, Cao Z, Liehr J, Stehlin JS. Dependence of anticancer activity of camptothecins on maintaining their lactone function. Ann New York Acad Sci 2000; 922: 27-35.
93. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992; 81: 676-84.
94. Mi Z, Burke TG. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry 1994; 33: 10325-6.
95. Opanasopit P, Yokoyama M, Watanabe M, Kawano K, Maitani Y, Okano T. Influence of serum and albumins from different species on stability of camptothecin-loaded micelles. J Control Release 2005; 104: 313-21.
96. Opanasopit P, Yokoyama M, Watanabe M, Kawano K, Maitani Y, Okano T. Block copolymer design for camptothecin incorporation into polymeric micelles for passive tumor targeting. Pharm Res 2004; 21: 2001-8.
97. Yamamoto T, Yokoyama M, Opanasopit P, Hayama A, Kawano K, Maitani Y. What are determining factors for stable drug incorporation into polymeric micelle carriers? Consideration on physical and chemical characters of the micelle inner core. J Control Release 2007; 123: 11-8.
98. Watanabe M, Kawano K, Yokoyama M, Opanasopit P, Okano T, Maitani Y. Preparation of camptothecin-loaded polymeric micelles and evaluation of their incorporation and circulation stability. Int J Pharm 2006; 308: 183-9.
99. Kawano K, Watanabe M, Yamamoto T, Yokoyama M, Opanasopit P, Okano T, Maitani Y. Enhanced antitumor effect of camptothecin loaded in long-circulating polymeric micelles. J Control Release 2006; 112: 329-32.
100. Bromberg LE, Ron ES. Protein and peptide release from temperature-responsive gels and thermogelling polymer matrices. Adv Drug Deliv Rev 1998; 31: 197-221.
101. Bromberg L. Synthesis and self-assembly of poly(ethylene oxide)- b-poly(propylene oxide)-b-poly(ethylene oxide)-g-poly(acrylic acid) gels. Ind Eng Chem Res 2001; 40: 2437-44.
102. Bromberg L, Temchenko M. Loading of hydrophobic compounds into micellar solutions of hydrophobically modified polyelectrolytes. Langmuir 1999; 15: 8627-32.
103. Bromberg L, Magner E. Release of hydrophobic compounds from micellar solutions of hydrophobically modified polyelectrolytes. Langmuir 1999; 15: 6792-8.
104. Bromberg L, Hatton TA, Barreiro-Iglesias R, Alvarez-Lorenzo C, Concheiro A. Controlled release camptothecin tablets based on pluronic and poly(acrylic acid) copolymer. effect of fabrication technique on drug stability, tablet structure, and release mode. Drug Dev Ind Pharm 2007; 33: 607-15.
105. Modi S, Jain JP, Domb AJ, Kumar N. Exploiting EPR in polymer drug conjugate delivery for tumor targeting. Curr Pharm Desing 2006; 12: 4785-96.
106. Greiesh K, Iyer AK, Fang J, Kawasuji M, Maeda H. Enhanced permeability and retention (EPR) effect and tumor-selective delivery of anticancer drugs. In: Torchilin VP (Ed.), Delivery of protein and peptide drugs in cancer, Imperial College Press, London, 2006, pp. 37-52.
107. Gaucher G, Dufresne MH, Sant VP, Kang N, Maysinger D, Leroux JC. Block copolymer micelles: preparation, characterization and application in drug delivery. J Control Release 2005; 109: 169-88.
108. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986; 46: 6387-92.
109. Maeda H, Wu J, Sawa T, Matsamura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84.
110. Harada A, Hideyuki T, Kataoka K. Physicochemical properties and nuclease resistance of antisense-oligodeoxynucleotides entrapped in the core of polyion complex micelles composed of PEG-poly(llysine) block copolymers. Eur J Pharm Sci 2001; 13: 35-42.
111. Kwon GS. Polymeric micelles for delivery of poorly water-soluble compounds. Crit Rev Ther Drug Carr Syst 2003; 20: 357-403.
112. Fox ME, Skoza FC, Frechet JMJ. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Accounts Chem Res 2009; 42: 1141-1151.
113. Maeda H, Fang J, Inutsuka T, Kitamoto Y. Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int Immunopharmacol 2003; 3: 319-28.
114. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009; 71: 409-19.
115. Duncan R, Gac-Breton S, Keane R, et al. Polymer-drug conjugates, PDEPT and PELT: basic principles for desing and transfer from the laboratory to clinic. J Control Release 2001; 74: 135-46.
116. Hori K, Nishihara M, Yokoyama M. Vital microscopic analysis of polymeric micelle extravasation from tumor vessels: macromolecular delivery according to tumor vascular growth stage. J Pharm Sci 2010; 99: 549-62.
117. Hara T, Iriyama S, Makino K, Terada H, Ohya M. Mathematical description of drug movement into tumor with EPR effect and estimation of its confirguration for DDS. Colloids Surf B: Biointerf 2010; 75: 42-6.
118. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today 2006; 11: 812-8.
119. Savic R, Luo L, Eisenberg A, Maysinger D. Micellar nanocontainers distribute to defined cytoplasmic organelles. Science 2003; 300: 615-8.
120. Zamboni WC. Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist 2009; 13: 248-60.
121. Gonzalez-López J, Sández I, Concheiro A, Alvarez-Lorenzo C. Poloxamines and poloxamers as polymeric micellar carriers for simvastatin: interactions at the air-water interface and in bulk solution. J Phys Chem C 2010; 114: 1181-9.
122. Husseini GA, Myrup GD, Pitt WG, Christensen DA, Rapoport NY. Factors affecting acoustically triggered release of drugs from polymeric micelles. J Control Release 2000; 69: 43-52.
123. Rapoport NY, Nam KH, Gao Z, Kennedy A. Application of ultrasound for targeted nanotherapy of malignant tumors. Acoust Phys 2009; 55: 594-601.
124. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427.
125. Loo TW, Clarke DM. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membrane Biol 2005, 206: 173-85.
126. Eckford PDW, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev 2009; 109: 2989-3011.
127. Leveque D, Jehl F. P-glycoprotein and pharmacokinetics. Anticancer Res 1995; 15: 331-6.
128. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976; 455: 152-62.
129. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-8.
130. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 1990; 38, 1277-87.
131. Gil S, Saura R, Forestier F, Farinotti R. P-glycoprotein expression of the human placenta during pregnancy. Placenta 2005; 26: 268-70.
132. Saito T, Zhang ZJ, Tsuzuki H, et al. P-glycoprotein expression of the human placenta during pregnancy. Brain Res 1997; 767: 388-92.
133. Edwards JE, Alcorn J, Savolainen J, Anderson BD, McNamara PJ. Role of P-glycoprotein in distribution of nelfinavir across the blood-mammary tissue barrier and blood-brain barrier. Antimicrob Agents Chemother 2005; 49: 1626-8.
134. Melaine N, Liénard MO, Dorval I, Le Goascogne C, Lejeune H, Jégou B. Multidrug resistance genes and P-glycoprotein in the testis of the rat, mouse, guinea pig, and human. Biol Reprod 2002; 67: 1699-1707.
135. Saito T, Zhang ZJ, Ohtsubo T, et al. Homozygous disruption of the mdr1a p-glycoprotein gene affects blood-nerve barrier function in mice administered with neurotoxic drugs. Acta Otolaryngol 2001; 121: 735-42.
136. Choudhuri S, Klaassen CD. Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol 2006; 25: 231-59.
137. Loo TW, Clarke DM. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membrane Biol 2005; 206: 173-85.
138. Garrigos M, Mir LM, Orlowski S. Competitive and noncompetitive inhibition of the multidrug-resistance-associated Pglycoprotein ATPase-Further experimental evidence for a multisite model. Eur J Biochem 1997; 244: 664-73.
139. Shaik N, Pan G, Elmquist WF. Interactions of Pluronic block copolymers on Pgp efflux activity: Experience with HIV-1 protease inhibitors. J Pharm Sci 2008; 97: 5421-33.
140. Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 2003; 55: 3-29.
141. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 2008; 9: 105-27.
142. Majumdar S, Duvvuri S, Mitra AK. Membrane transporter/ receptor-targeted prodrug design: strategies for human and veterinary drug development. Adv Drug Deliv Rev 2004; 56: 1437-52.
143. Girardin F. Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin Neurosci 2006; 8: 311-21.
144. Varma MV, Perumal OP, Panchagnula R. Functional role of Pglycoprotein in limiting peroral drug absorption:optimizing drug delivery. Curr Opin Chem Biol 2006; 10: 367-73.
145. Woo JS, Lee CH, Shim CK, Hwang SJ. Enhanced oral bioavailability of paclitaxel by coadministration of the Pglycoprotein inhibitor KR30031. Pharmacol Res 2003; 20: 24-30.
146. Banerjee SK, Jagannath C, Hunter RL, Dasgupta A. Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein. Life Sci 2000; 67: 2011-6.
147. Bernkop-Schnürch A, Grabovac V. Polymeric efflux pump inhibitors in oral drug delivery. Am J Drug Del 2006; 4: 263-72.
148. Pardridge WM. Introduction to the Blood-Brain Barrier. Methodology, Biology and Pathology, Cambridge University Press, Cambridge, 1998.
149. Batrakova EV, Miller DW, Li S, Alakhov V, Kabanov AV, Elmquist WF. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther 2001; 296: 551-7.
150. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987; 84: 265-9.
151. Goldstein LJ, Galski H, Fojo A, et al. Expression of multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116-24.
152. Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 87: 7160-4.
153. Penson RT, Oliva E, Skates SJ, et al. Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 2004; 93: 98-106.
154. Cabrera MA, González I, Fernández C, Navarro C, Bermejo M. A topological substructural approach for the prediction of Pglycoprotein substrates. J Pharm Sci 2006; 95: 589-606.
155. Eytan GD, Regev R, Oren G, Assaraf YG. The role of passive transbilayer drug movement in multidrug resistance and its modulation. J Biol Chem 1996; 271: 12897-902.
156. Broxterman HJ, Pinedo HM, Kuiper CM, Kaptein LC, Schuurhuis GJ, Lankelma J. Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells. FASEB J 1988; 2: 2278-82.
157. Demina T, Grozdova I, Krylova O, et al. Relationship between the structure of amphiphilic copolymers and their ability to disturb lipid bilayers. Biochemistry 2005; 44: 4042-54.
158. Werle M. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res 2008; 25: 500-11.
159. Carreno-Gomez B, Duncan R. Compositions with enhanced oral bioavailability. USP 20030211072, 2002.
160. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002; 54: 759-79.
161. D'Emanuele A, Jevprasesphant R, Penny J, Attwood D. The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability. J Control Release 2004; 95: 447-53.
162. Grabovac V, Bernkop-Schnürch A. Thiolated polymers as effective inhibitors of intestinal MRP2 efflux pump transporters. Sci Pharm 2006; 74: 75.
163. Föger F, Hoyer H, Kafedjiiski K, Thaurer M, Bernkop-Schnürch A. In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein. Biomaterials 2006; 27: 5855-60.
164. Bernkop-Schnürch A, Grabovac V. Polymeric efflux pump inhibitors in oral drug delivery. Am J Drug Del 2006; 4: 263-72.
165. Shen Q, Lin Y, Handa T, et al. Modulation of intestinal Pglycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm 2006; 313: 49-56.
166. Hugger ED, Audus KL, Borchardt RT. Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers. J Pharm Sci 2002; 91:1980-90.
167. Hugger D, Novak BL, Burton PS, Audus KL, Borchardt RT. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 2002; 91: 1991-2002.
168. Zastre JA, Jackson JK, Wong W, Burt HM. Evidence for modulation of P-glycoprotein-mediated efflux by methoxypolyethylene glycol-block-polycaprolactone amphiphilic diblock copolymers. Pharm Res 2004; 21: 1489-97.
169. Zastre JA, Jackson JK, Wong W, Burt HM. P-glycoprotein efflux inhibition by amphiphilic diblock copolymers: relationship between copolymer concentration and substrate hydrophobicity. Mol Pharm 2008; 5: 643-53.
170. Miller DW, Batrakova EV, Waltner DO, Alakhov V, Kabanov AV. Interactions of pluronic block copolymers with brain microvessel endothelial cells: evidence for two potential pathways for drug absorption. Bioconjug Chem 1997; 8: 649-57.
171. Kopecek J, Kopeckova P, Minko T, Lu Z. HPMA copolymeranticancer drug conjugates: design, activity, and mechanism of action. Eur J Pharm Biopharm 2000; 50: 61-81.
172. Kopecek J, Kopeckova P, Minko T, Lu ZR, Peterson CM. Water soluble polymers in tumor targeted delivery. J Control Release 2001; 74: 147-58.
173. Alakhov V, Klinksi E, Li S, et al. Block copolymer based formulation of doxorubicin. From cell screen to clinical trials. Colloid Surf B: Biointerf 1999; 16: 113-34.
174. Batrakova EV, Li S, Li Y, Alakhov VY, Kabanov AV. Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 2004; 21: 2226-33.
175. Alakhov V, Moskaleva EY, Batrakova EV, Kabanov AV. Hypersensitization of multidrug resistant human ovarian carcinoma cells by Pluronic P85 block copolymer. Bioconjugate Chem 1996; 7: 209-16.
176. Alakhova DY, Rapoport NY, Batrakova EV, et al. Differential metabolic responses to pluronic in MDR and non-MDR cells: A novel pathway for chemosensitization of drug resistant cancers. J Control Release 2010; 142: 89-100.
177. Batrakova EV, Li S, Vinogradov SV, Alakhov V, Miller DW, Kabanov AV. Mechanism of pluronic effect on P-glycoprotein efflux system in blood brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 2001; 299: 483-93.
178. Batrakova EV, Li S, Elmquist WF, Miller DW, Alakhov VY, Kabanov AV. Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br J Cancer 2001; 85: 1987-97.
179. Minko T, Batrakova EV, Li S, et al. Pluronic block copolymers alter apoptotic signal transduction of doxorubicin in drug-resistant cancer cells. J Control Release 2005; 105: 269-78.
180. Sharma AK, Zhang L, Li S, et al. Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant. J Control Release 2008; 131: 220-7.
181. Kabanov AV, Batrakova EV, Alakhov VY. An essential relationship between ATP depletion and chemosensitizing activity of Pluronic block copolymers. J Control Release 2003; 91: 75-83.
182. Johnson BM, Charman WN, Porter CJH. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85 and vitamin E d-alpha-tocopheryl polyethylene glycol 1000 succinate on Pglycoprotein efflux and enterocyte-based metabolism in excised rat intestine. AAPS Pharm Sci 2002; 4: article 40.
183. Witt KA, Huber JD, Egleton RD, Davis TP. Pluronic P85 block copolymer enhances opioid peptide analgesia. J Pharmacol Exp Ther 2002; 303: 760-7.
184. Kabanov AV, Batrakova EV, Miller DW. Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv Drug Deliv Rev 2003; 55: 151-64.
185. Batrakova EV, Zhang Y, Li Y, et al. Effects of Pluronic P85 on GLUT1 and MCT1 Transporters in the Blood-Brain Barrier. Pharm Res 2004; 21: 1993-2000.
186. Evers R, Kool M, Smith AJ, van Deemter L, de Haas M, Borst P. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport. Br J Cancer 2000; 83: 366-74.
187. Armstrong JBA, Newman C, Alakhov V, et al. SP1049C as firstline therapy in advanced (inoperable or metastic) adenocarcinoma of the oesophagus: a phase II window study. J Clin Oncol 2006; 24: 4080.
188. Yamagata T, Kusuhara H, Morishita M, Takayama K, Benameur H, Sugiyama Y. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients. Drug Metab Dispos 2007; 35: 1142-8.
189. Bromberg L, Alakhov V. Effects of polyether-modified poly(acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers. J Control Release 2003; 88: 11-22.
190. Batrakova EV, Han HY, Alakhov VY, Miller DW, Kabanov AV. Effect of Pluronic block copolymers on drug absorption in Caco-2 cell monolayers. Pharm Res 1998; 15: 852-7.
191. Slepnev VI, Kuznetsova LE, Gubin AN, Batrakova EV, Alakhov VY, Kabanov AV. Micelles of poly(oxyethylene)- poly(oxypropylene) block copolymer (pluronic) as a tool for lowmolecular compound delivery into a cell. Phosphorylation of intracellular proteins with micelle incorporated [γ-32P] ATP. Biochem Mol Biol Int 1992; 26: 587-95.
192. Venne A, Li S, Mandeville R, Kabanov A, Alakhov V. Hypersensitizing effect of Pluronic L61 on cytotoxic activity, transport and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 1996; 56: 3626-9.
193. Batrakova EV, Li S, Alakhov VY, Miller DW, Kabanov AV. Optimal structure requirements for Pluronic block copolymers in modifying P-glycoprotein drug efflux transporter activity in bovine brain microvessel endothelial cells. J Pharmacol Exp Ther 2003; 304: 845-54.
194. Alvarez-Lorenzo C, Rey-Rico A, Brea J, Loza MI, Concheiro A, Sosnik A. Inhibition of P-glycoprotein pumps by PEO-PPO amphiphiles: Branched versus linear derivatives. Nanomedicine UK 2010; 5: 1371-83.
195. Firestone MA, Wolf AC, Seifert S. Small-angle X-ray scattering study of the interaction of poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) triblock copolymers with lipid bilayers. Biomacromolecules 2003; 4: 1539-49.
196. Lee B, Firestone MA. Electron density mapping of triblock copolymers associated with model biomembranes: Insights into conformational states and effect on bilayer structure. Biomacromolecules 2008; 9: 1541-50.
197. Matsamura Y, Kataoka K. Preclinical and clinical studies of anticancer agentincorporating polymeric micelles. Cancer Sci 2009; 100: 572-9.
198. Danson S, Ferry D, Alakhov V, et al M. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 2004; 90: 2085-91.
199. Lee KS, Chung HC, Im SA, et al. Multicenter phase II trials of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer. Breast Cancer Res Treat 2008; 108: 241-50.
200. Hamaguchi T, Matsamura Y, Suzuki M, et al. NK105, a paclitaxelincorporating micellar nanoparticle formation, can extend in vivo antitumor activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 2005; 92: 1240-6.
201. http://www.nipponkayaku.co.jp (accessed on June 2010).
202. http://www.nanocarrier.co.jp (accessed on June 2010).
203. http://clinicaltrials.gov/ct2/results?term=genexol+PM (accessed on June 2010).
204. http://www.supratek.com (accessed on June 2010).